The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of multiple doses of intravenous DT-216 in adult patients with Friedrich Ataxia.
1 Primary · 1 Secondary · Reporting Duration: Up to approximately 60 days
Experimental Treatment
Non-Treatment Group
38 Total Participants · 2 Treatment Groups
Primary Treatment: Multiple Dose: DT-216 · Has Placebo Group · Phase 1
Age 18 - 55 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: